Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(13 sites)

United States

Brigham & Women's Hospital, Boston, Massachusetts

The Cleveland Clinic Foundation, Cleveland, Ohio

Belgium

UZ Leuven, Leuven, Vlaams Brabant

Denmark

Rigshospitalet Department of Digestive Diseases, Transplantation and General Surgery Section for Intestinal Failure, Copenhagen

France

Hopital Beaujon, Clichy, Clichy

Centre Hospitalier Universitaire de Bordeaux, Bordeaux

Les Hospices Civils de Lyon, Lyon

Centre Hospitalier Universitaire de Nice, Nice

Germany

Asklepios Klinik St. Georg, Hamburg, Free and Hanseatic City of Hamburg

Universitätsklinikum Tübingen, Tübingen, Tübingen

Poland

Wojewodzki Specjalistyczny Szpital im. Mikołaja Pirogowa w Łodzi, Lodz, Łódź Voivodeship

South Korea

Samsung Medical Center, Seoul

United Kingdom

Central Middlesex Hospital, London